MedPath

To know the effect of drug Nalbuphine and Ketamine in treating shivering in patients coming for below abdomen Surgeries

Not yet recruiting
Conditions
Medical and Surgical,
Registration Number
CTRI/2023/02/049546
Lead Sponsor
ESI medical college and hospital
Brief Summary

Title of the research work:

Comparision of Nalbuphine versus Ketamine for treating post anaesthtic shivering after spinal anaesthesia in patients undergoing infra umbilical surgeries

Introduction and Need for the study:

Shivering is known to be a frequent complication, reported in 40 to 70 % of patients undergoing surgery under regional anesthesia.(1,2) Post-anesthetic shivering is spontaneous involuntary, rhythmic, oscillating, tremor-like muscle hyperactivity that increases metabolic heat production up to 600% after general or regional anesthesia .(3) Post anesthetic shivering may cause discomfort to patients, and aggravate wound pain by stretching incisions and increase intracranial (4) and intraocular (5) pressure. Various methods are available for control of shivering; these may be non pharmacological or pharmacological methods using drugs which have anti-shivering properties.

Nalbuphine, a semisynthetic opioid related to both Naloxone and Oxymorphone, has the characteristics of μ-antagonist and κ-agonist activities. It has a high affinity for κ-opioid receptors in the central nervous system. Therefore, Nalbuphine got a significant effect on post spinal anesthesia shivering. But Nalbuphine associated with many side effects like respiratory depression, urinary retention, nausea, vomiting, sedation and pruritus (6-9)

Ketamine has also been used as an anti-shivering drug. It is a non-competitive N-methy-D-aspartate (NMDA) receptor antagonist. Ketamine increases arterial pressure, heart rate, and cardiac output because of direct central sympathetic stimulation and inhibition of norepinephrine uptake into postganglionic sympathetic nerve endings, and may decrease core-to-peripheral redistribution of heat(10). Thus helps in prevention of shivering.

It is used as antishivering agent in dose of 0.5-0.75mg kg-1 IV. But even in these doses it causes side effects i.e. drowsiness, hallucination and delirium.(11-14)

So we conducted the present study to evaluate and compare the relative efficacy and safety of low dose Ketamine (0.25 mg/kg) and Nalbuphine (0.1mg/kg) for prevention of shivering in ASA 1 and 2 patients during spinal anaesthesia.

Objectives:

1) Primary objective- To evaluate and compare the relative efficacy and safety of low dose Ketamine (0.25 mg/kg) and Nalbuphine (0.1mg/kg) for prevention of shivering in ASA 1 and 2 patients during spinal anaesthesia.

2) Secondary objective- To assess any side effects like respiratory depression, urinary retention, nausea, vomiting, sedation and pruritus due to Nalbuphine and drowsiness, hallucination and delirium due to Ketamine .

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Patient’s belonging to ASA 1 and 2 Scheduled for infra umbilical surgeries Patient’s without having any comorbidities.

Exclusion Criteria

Patients belonging to ASA3 or more Pregnant women Patients less than 18 years Patient not willing.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1) Shivering scoreT1: 10 minutes after spinal anesthesia | T2: 20 minutes after spinal anesthesiaT3 within 24 hours
Secondary Outcome Measures
NameTimeMethod
Any side effects - To assess any side effects like respiratory depression, urinary retention, nausea, vomiting, sedation, pruritus, drowsiness, hallucination and delirium will be noted.

Trial Locations

Locations (1)

ESI medical college operation theatre

🇮🇳

Gulbarga, KARNATAKA, India

ESI medical college operation theatre
🇮🇳Gulbarga, KARNATAKA, India
Dr Gayatri CK
Principal investigator
9916571034
ck.gayatri@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.